Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signature
暂无分享,去创建一个
U. Ala | L. Marconato | L. Aresu | F. Bertoni | D. Giannuzzi | Luca Licenziato | R. De Maria | S. Iussich | L. Minoli | A. Fanelli | Antonella Fanelli | Giulia Orlando | L. Licenziato | G. Orlando
[1] P. Fariselli,et al. The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications , 2022, Lab Animal.
[2] Guangyao Li,et al. IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer , 2022, Journal of oncology.
[3] M. Takahara,et al. IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer , 2022, Translational oncology.
[4] M. Xiao,et al. Bioinformatics analysis for the biomarkers of the tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma , 2021, Translational cancer research.
[5] L. Marconato,et al. Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope , 2021, Veterinary sciences.
[6] Yanlin Huang,et al. Prognostic Value of Complement Component 2 and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma , 2020, BioMed research international.
[7] A. Avery. The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma , 2020, Frontiers in Oncology.
[8] C. Sautès-Fridman,et al. Context-dependent roles of complement in cancer , 2019, Nature Reviews Cancer.
[9] L. Marconato,et al. Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. , 2019, Research in veterinary science.
[10] L. Marconato,et al. Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers , 2019, Journal of Immunotherapy for Cancer.
[11] Shu Li,et al. BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies , 2019, Journal of Cancer.
[12] L. Cascione,et al. New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease , 2018, Haematologica.
[13] L. Pasqualucci,et al. Genetics of diffuse large B-cell lymphoma. , 2018, Blood.
[14] V. Afshar-Kharghan. The role of the complement system in cancer , 2017, The Journal of clinical investigation.
[15] L. Aresu. Canine Lymphoma, More Than a Morphological Diagnosis: What We Have Learned about Diffuse Large B-Cell Lymphoma , 2016, Front. Vet. Sci..
[16] G. Multhoff,et al. Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer , 2016, Front. Immunol..
[17] A. Pierini,et al. Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation. , 2015, Veterinary and comparative oncology.
[18] L. Marconato,et al. Peripheral blood lymphocyte/monocyte ratio as a useful prognostic factor in dogs with diffuse large B-cell lymphoma receiving chemoimmunotherapy. , 2015, Veterinary journal.
[19] F. Rossi,et al. Randomized, Placebo-Controlled, Double-Blinded Chemoimmunotherapy Clinical Trial in a Pet Dog Model of Diffuse Large B-cell Lymphoma , 2013, Clinical Cancer Research.
[20] D. Argyle,et al. Comparative Gene Expression Profiling Identifies Common Molecular Signatures of NF-κB Activation in Canine and Human Diffuse Large B Cell Lymphoma (DLBCL) , 2013, PloS one.
[21] L. Marconato,et al. Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: prognostic significance and proposal of a cut-off value. , 2013, Veterinary journal.
[22] C. Fan,et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. , 2013, Cancer research.
[23] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[24] M. Miller,et al. Classification of Canine Malignant Lymphomas According to the World Health Organization Criteria , 2011, Veterinary pathology.
[25] C. Khanna,et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2010, Veterinary and comparative oncology.
[26] M. Mazzilli,et al. Aberrant phenotypes and quantitative antigen expression in different subtypes of canine lymphoma by flow cytometry. , 2008, Veterinary immunology and immunopathology.
[27] Jeremy J. W. Chen,et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.
[28] R. Gascoyne,et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. , 2006, Blood.
[29] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[30] Yuko Takeba,et al. Txk, a Member of Nonreceptor Tyrosine Kinase of Tec Family, Acts as a Th1 Cell-Specific Transcription Factor and Regulates IFN-γ Gene Transcription1 , 2002, The Journal of Immunology.
[31] R Tibshirani,et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. , 2001, Blood.
[32] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[33] J. Lunceford,et al. IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .